Johnson & Johnson (NYSE:JNJ) Shares Sold by Verus Capital Partners LLC

Verus Capital Partners LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,693 shares of the company’s stock after selling 214 shares during the period. Verus Capital Partners LLC’s holdings in Johnson & Johnson were worth $901,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Capital Square LLC increased its holdings in shares of Johnson & Johnson by 19.0% in the 1st quarter. Capital Square LLC now owns 4,471 shares of the company’s stock worth $707,000 after acquiring an additional 713 shares during the period. Meeder Advisory Services Inc. increased its holdings in shares of Johnson & Johnson by 0.7% in the 1st quarter. Meeder Advisory Services Inc. now owns 29,056 shares of the company’s stock worth $4,596,000 after acquiring an additional 215 shares during the period. Meeder Asset Management Inc. increased its holdings in shares of Johnson & Johnson by 326.2% in the 1st quarter. Meeder Asset Management Inc. now owns 132,856 shares of the company’s stock worth $21,016,000 after acquiring an additional 101,683 shares during the period. Sfmg LLC increased its holdings in shares of Johnson & Johnson by 2.3% in the 1st quarter. Sfmg LLC now owns 14,344 shares of the company’s stock worth $2,269,000 after acquiring an additional 327 shares during the period. Finally, Sei Investments Co. increased its holdings in shares of Johnson & Johnson by 9.9% in the 1st quarter. Sei Investments Co. now owns 1,017,453 shares of the company’s stock worth $160,950,000 after acquiring an additional 91,297 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

JNJ traded up $0.88 during trading on Tuesday, reaching $150.12. 1,345,227 shares of the company’s stock were exchanged, compared to its average volume of 7,228,327. The company has a market capitalization of $361.29 billion, a P/E ratio of 9.37, a PEG ratio of 2.52 and a beta of 0.52. The business has a 50 day moving average price of $147.95 and a 200 day moving average price of $153.41. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.97. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The company had revenue of $21.38 billion during the quarter, compared to analysts’ expectations of $21.39 billion. During the same period last year, the business earned $2.68 earnings per share. The business’s revenue was up 2.3% on a year-over-year basis. As a group, analysts predict that Johnson & Johnson will post 10.5 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Bank of America decreased their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. HSBC upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and raised their price objective for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. Morgan Stanley reduced their price objective on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 17th. Royal Bank of Canada reissued an “outperform” rating and issued a $175.00 price target on shares of Johnson & Johnson in a research report on Monday, June 17th. Finally, The Goldman Sachs Group started coverage on shares of Johnson & Johnson in a research report on Thursday, May 30th. They issued a “neutral” rating and a $160.00 price target for the company. Eight investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $174.07.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.